Spectroscopic MRI Guided Proton Therapy for Pediatric High-Grade Glioma (RAD4500)
This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.
• Pathologically diagnosed high-grade glioma (World Health Organization \[WHO\] grade 3-4). Patients with a radiographically diagnosed high-grade glioma may enroll prior to pathologic confirmation, but would be removed from study if pathology did not confirm the diagnosis of high-grade glioma.
• Primary tumor located within the supratentorial brain.
• Recommended to receive definitive radiation therapy.
• Able to receive MRI scans.
• Both males and females, and members of all races and ethnic groups are eligible for this trial.